TrialEuropean journal of neurology2022

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.

Marco Battaglini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.